LAND Co., Ltd. (TYO:8918)
Japan · Delayed Price · Currency is JPY 9.00
-1.00 (-10.00%)
Aug 1, 2025, 3:30 PM JST
Verve Therapeutics Income Statement
Financials in millions JPY. Fiscal year is March - February.
Millions JPY. Fiscal year is Mar - Feb.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | May '25 May 31, 2025 | Feb '25 Feb 28, 2025 | Feb '24 Feb 29, 2024 | Feb '23 Feb 28, 2023 | Feb '22 Feb 28, 2022 | Feb '21 Feb 28, 2021 | 2017 - 2021 |
| 5,186 | 5,092 | 2,101 | 4,102 | 3,026 | 1,141 | Upgrade | |
Revenue Growth (YoY) | 174.68% | 142.36% | -48.78% | 35.56% | 165.21% | -60.35% | Upgrade |
Cost of Revenue | 3,425 | 3,350 | 1,169 | 2,139 | 997 | 3,413 | Upgrade |
Gross Profit | 1,761 | 1,742 | 932 | 1,963 | 2,029 | -2,272 | Upgrade |
Selling, General & Admin | 638 | 631 | 654 | 562 | 579 | 553 | Upgrade |
Other Operating Expenses | 135 | 135 | 68 | 92 | - | - | Upgrade |
Operating Expenses | 772 | 765 | 702 | 669 | 464 | 552 | Upgrade |
Operating Income | 989 | 977 | 230 | 1,294 | 1,565 | -2,824 | Upgrade |
Interest Expense | -15 | -15 | -45 | -15 | -15 | -13 | Upgrade |
Interest & Investment Income | 14 | 12 | 26 | 41 | 14 | 16 | Upgrade |
Other Non Operating Income (Expenses) | 3 | -4 | 42 | 36 | 28 | 32 | Upgrade |
EBT Excluding Unusual Items | 991 | 970 | 253 | 1,356 | 1,592 | -2,789 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | 78 | - | Upgrade |
Other Unusual Items | - | - | - | - | 1 | - | Upgrade |
Pretax Income | 991 | 970 | 253 | 1,356 | 1,671 | -2,789 | Upgrade |
Income Tax Expense | 96 | 96 | 13 | 80 | 1 | - | Upgrade |
Net Income | 895 | 874 | 240 | 1,276 | 1,670 | -2,789 | Upgrade |
Net Income to Common | 895 | 874 | 240 | 1,276 | 1,670 | -2,789 | Upgrade |
Net Income Growth | 558.09% | 264.17% | -81.19% | -23.59% | - | - | Upgrade |
Shares Outstanding (Basic) | 1,521 | 1,500 | 1,438 | 1,434 | 1,435 | 1,441 | Upgrade |
Shares Outstanding (Diluted) | 1,524 | 1,503 | 1,440 | 1,434 | 1,435 | 1,441 | Upgrade |
Shares Change (YoY) | 5.44% | 4.38% | 0.45% | -0.10% | -0.38% | -1.36% | Upgrade |
EPS (Basic) | 0.59 | 0.58 | 0.17 | 0.89 | 1.16 | -1.94 | Upgrade |
EPS (Diluted) | 0.59 | 0.58 | 0.17 | 0.89 | 1.16 | -1.94 | Upgrade |
EPS Growth | 521.79% | 247.57% | -81.25% | -23.51% | - | - | Upgrade |
Free Cash Flow | - | 2,103 | -1,392 | 1,119 | 911 | 130 | Upgrade |
Free Cash Flow Per Share | - | 1.40 | -0.97 | 0.78 | 0.64 | 0.09 | Upgrade |
Dividend Per Share | 0.100 | 0.100 | 0.100 | 0.100 | 0.100 | - | Upgrade |
Gross Margin | 33.96% | 34.21% | 44.36% | 47.85% | 67.05% | -199.12% | Upgrade |
Operating Margin | 19.07% | 19.19% | 10.95% | 31.55% | 51.72% | -247.50% | Upgrade |
Profit Margin | 17.26% | 17.16% | 11.42% | 31.11% | 55.19% | -244.44% | Upgrade |
Free Cash Flow Margin | - | 41.30% | -66.25% | 27.28% | 30.11% | 11.39% | Upgrade |
EBITDA | 993.5 | 982 | 237 | 1,300 | 1,568 | -2,821 | Upgrade |
EBITDA Margin | 19.16% | 19.29% | 11.28% | 31.69% | 51.82% | -247.24% | Upgrade |
D&A For EBITDA | 4.5 | 5 | 7 | 6 | 3 | 3 | Upgrade |
EBIT | 989 | 977 | 230 | 1,294 | 1,565 | -2,824 | Upgrade |
EBIT Margin | 19.07% | 19.19% | 10.95% | 31.55% | 51.72% | -247.50% | Upgrade |
Effective Tax Rate | 9.69% | 9.90% | 5.14% | 5.90% | 0.06% | - | Upgrade |
Updated Jan 9, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.